The multi‑functional technological upgrade project for Workshop No. 5 of Huanggang Zhongyou Bio has completed its filing, adding an annual production capacity of 1,200 tons of alkaloids.

Recently, the multifunctional technological upgrade project for Workshop No. 5 of Huanggang Zhongyou Biotechnology Co., Ltd. has been officially completed and publicly announced for record‑keeping purposes. The project involves a total investment of RMB 20 million and is being implemented by upgrading and renovating existing plant facilities and utility infrastructure, thereby making full use of the available production space. It also introduces new integrated core process equipment for reaction, distillation, and extraction, establishing a flexible, multi‑functional alkaloid production line.

The global smokeless nicotine market is expanding steadily, and the compliant development of pharmaceutical alkaloids is accelerating.

The global market for smokeless nicotine products—such as nicotine pouches and snus—has maintained steady growth, driving a sustained increase in demand for alkaloid raw materials like high-purity levonornicotine and nicotine salts. Meanwhile, regulatory frameworks in overseas markets are becoming increasingly clear, prompting customers to impose stricter requirements on raw-material purity, impurity control, and the compliance credentials of manufacturing facilities.

Green synthesis and biocatalysis technologies are driving the iterative upgrading of the alkaloid industry.

Alkaloids, as important natural products, are widely used in the development of innovative pharmaceuticals and health‑care consumer products. Conventional plant‑extraction processes are hampered by seasonal variability of raw materials, high consumption of organic solvents, and elevated costs associated with separation and purification; meanwhile, traditional chemical synthesis routes suffer from high catalyst expenses and a large number of by‑products.

Flexible production line upgrades have become the mainstream approach for leading alkaloid manufacturers seeking to expand capacity.

In recent years, demand has continued to grow for alkaloid‑derived pharmaceutical raw materials and smokeless nicotine products, leading to a marked shift in the industry’s capacity‑expansion strategy. Compared with the capital‑intensive approach of building new facilities, upgrading existing workshops with versatile, flexible technologies has become the preferred choice for leading companies. Fine‑chemical alkaloid production is characterized by a wide variety of products, small batch sizes, and customization, making it difficult for single‑purpose production lines to meet the market’s diversified order requirements. By retrofitting and upgrading distillation, extraction, and reaction units to create flexible production lines capable of switching between product formulations, companies can effectively leverage existing plant space and utility infrastructure, significantly reduce fixed‑asset investment, and shorten project construction timelines.